These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 30219060

  • 1. BAR-encapsulated nanoparticles for the inhibition and disruption of Porphyromonas gingivalis-Streptococcus gordonii biofilms.
    Mahmoud MY, Demuth DR, Steinbach-Rankins JM.
    J Nanobiotechnology; 2018 Sep 15; 16(1):69. PubMed ID: 30219060
    [Abstract] [Full Text] [Related]

  • 2. Peptide-modified nanoparticles inhibit formation of Porphyromonas gingivalis biofilms with Streptococcus gordonii.
    Kalia P, Jain A, Radha Krishnan R, Demuth DR, Steinbach-Rankins JM.
    Int J Nanomedicine; 2017 Sep 15; 12():4553-4562. PubMed ID: 28790818
    [Abstract] [Full Text] [Related]

  • 3. Functional assessment of peptide-modified PLGA nanoparticles against oral biofilms in a murine model of periodontitis.
    Mahmoud MY, Steinbach-Rankins JM, Demuth DR.
    J Control Release; 2019 Mar 10; 297():3-13. PubMed ID: 30690103
    [Abstract] [Full Text] [Related]

  • 4. Structural dissection and in vivo effectiveness of a peptide inhibitor of Porphyromonas gingivalis adherence to Streptococcus gordonii.
    Daep CA, Novak EA, Lamont RJ, Demuth DR.
    Infect Immun; 2011 Jan 10; 79(1):67-74. PubMed ID: 21041492
    [Abstract] [Full Text] [Related]

  • 5. Rapid Release Polymeric Fibers for Inhibition of Porphyromonas gingivalis Adherence to Streptococcus gordonii.
    Mahmoud MY, Sapare S, Curry KC, Demuth DR, Steinbach-Rankins JM.
    Front Chem; 2019 Jan 10; 7():926. PubMed ID: 32039149
    [Abstract] [Full Text] [Related]

  • 6. Structural characterization of peptide-mediated inhibition of Porphyromonas gingivalis biofilm formation.
    Daep CA, James DM, Lamont RJ, Demuth DR.
    Infect Immun; 2006 Oct 10; 74(10):5756-62. PubMed ID: 16988253
    [Abstract] [Full Text] [Related]

  • 7. Tobacco smoke augments Porphyromonas gingivalis-Streptococcus gordonii biofilm formation.
    Bagaitkar J, Daep CA, Patel CK, Renaud DE, Demuth DR, Scott DA.
    PLoS One; 2011 Oct 10; 6(11):e27386. PubMed ID: 22110637
    [Abstract] [Full Text] [Related]

  • 8. Natural antigenic differences in the functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a means for targeted biofilm therapeutics.
    Rocco CJ, Davey ME, Bakaletz LO, Goodman SD.
    Mol Oral Microbiol; 2017 Apr 10; 32(2):118-130. PubMed ID: 26988714
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interaction of Porphyromonas gingivalis with oral streptococci requires a motif that resembles the eukaryotic nuclear receptor box protein-protein interaction domain.
    Daep CA, Lamont RJ, Demuth DR.
    Infect Immun; 2008 Jul 10; 76(7):3273-80. PubMed ID: 18474648
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 1,2,3-Triazole-based inhibitors of Porphyromonas gingivalis adherence to oral streptococci and biofilm formation.
    Patil PC, Tan J, Demuth DR, Luzzio FA.
    Bioorg Med Chem; 2016 Nov 01; 24(21):5410-5417. PubMed ID: 27647373
    [Abstract] [Full Text] [Related]

  • 13. Assessment of CafA Targeted BAR-Encapsulated Nanoparticles against Oral Biofilms.
    Desai H, Mahmoud MY, Tan J, Minooei F, Demuth DR, Steinbach-Rankins JM.
    Pharmaceutics; 2020 Sep 01; 12(9):. PubMed ID: 32882864
    [Abstract] [Full Text] [Related]

  • 14. Selective substitution of amino acids limits proteolytic cleavage and improves the bioactivity of an anti-biofilm peptide that targets the periodontal pathogen, Porphyromonas gingivalis.
    Daep CA, Novak EA, Lamont RJ, Demuth DR.
    Peptides; 2010 Dec 01; 31(12):2173-8. PubMed ID: 20800634
    [Abstract] [Full Text] [Related]

  • 15. Erythritol alters microstructure and metabolomic profiles of biofilm composed of Streptococcus gordonii and Porphyromonas gingivalis.
    Hashino E, Kuboniwa M, Alghamdi SA, Yamaguchi M, Yamamoto R, Cho H, Amano A.
    Mol Oral Microbiol; 2013 Dec 01; 28(6):435-51. PubMed ID: 23890177
    [Abstract] [Full Text] [Related]

  • 16. Antibacterial activities of natural lichen compounds against Streptococcus gordonii and Porphyromonas gingivalis.
    Sweidan A, Chollet-Krugler M, Sauvager A, van de Weghe P, Chokr A, Bonnaure-Mallet M, Tomasi S, Bousarghin L.
    Fitoterapia; 2017 Sep 01; 121():164-169. PubMed ID: 28736072
    [Abstract] [Full Text] [Related]

  • 17. Targeting the HUβ Protein Prevents Porphyromonas gingivalis from Entering into Preexisting Biofilms.
    Rocco CJ, Bakaletz LO, Goodman SD.
    J Bacteriol; 2018 Jun 01; 200(11):. PubMed ID: 29437850
    [Abstract] [Full Text] [Related]

  • 18. The effect of lactoferrin on oral bacterial attachment.
    Arslan SY, Leung KP, Wu CD.
    Oral Microbiol Immunol; 2009 Oct 01; 24(5):411-6. PubMed ID: 19702956
    [Abstract] [Full Text] [Related]

  • 19. Disruption of heterotypic community development by Porphyromonas gingivalis with small molecule inhibitors.
    Wright CJ, Wu H, Melander RJ, Melander C, Lamont RJ.
    Mol Oral Microbiol; 2014 Oct 01; 29(5):185-93. PubMed ID: 24899524
    [Abstract] [Full Text] [Related]

  • 20. In Vitro and In Vivo Activity of Peptidomimetic Compounds That Target the Periodontal Pathogen Porphyromonas gingivalis.
    Tan J, Patil PC, Luzzio FA, Demuth DR.
    Antimicrob Agents Chemother; 2018 Jul 01; 62(7):. PubMed ID: 29760142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.